{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:23:08Z","timestamp":1792167788583,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ctrv.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T00:53:18Z","timestamp":1433638398000},"page":"777-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["TAS-102, a novel antitumor agent: A review of the mechanism of action"],"prefix":"10.1016","volume":"41","author":[{"given":"Heinz-Josef","family":"Lenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2015.06.001_b0005","first-page":"3","article-title":"On the rational development of a new drug: the example of the fluorinated pyrimidines","volume":"65","author":"Heidelberger","year":"1981","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.1016\/j.ctrv.2015.06.001_b0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","article-title":"Standing the test of time: targeting thymidylate biosynthesis in cancer therapy","volume":"11","author":"Wilson","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0015","first-page":"5579","article-title":"ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study","volume":"51","author":"Jackman","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0020","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1349-7006.2007.00477.x","article-title":"Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies","volume":"98","author":"Temmink","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.06.001_b0035","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.06.001_b0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1535-6108(04)00080-7","article-title":"Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme","volume":"5","author":"Rahman","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2015.06.001_b0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.3099389","article-title":"Atomic structure of thymidylate synthase: target for rational drug design","volume":"235","author":"Hardy","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2015.06.001_b0050","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1073\/pnas.69.7.1855","article-title":"5-Fluoro-2\u2032-deoxyuridylate: covalent complex with thymidylate synthetase","volume":"69","author":"Santi","year":"1972","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2015.06.001_b0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","article-title":"Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate","volume":"13","author":"Santi","year":"1974","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2015.06.001_b0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4684-1248-2_15","article-title":"Mechanism of thymineless death","volume":"195","author":"Goulian","year":"1986","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0065","first-page":"2346","article-title":"Mechanism of cell death following thymidylate synthase inhibition: 2\u2032-deoxyuridine-5\u2032-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole","volume":"51","author":"Curtin","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00018-008-8557-5","article-title":"Participation of DNA repair in the response to 5-fluorouracil","volume":"66","author":"Wyatt","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2015.06.001_b0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0092-8674(78)90089-2","article-title":"The incorporation of uracil into animal cell DNA in vitro","volume":"15","author":"Grafstrom","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2015.06.001_b0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1054\/bjoc.2001.1921","article-title":"The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition","volume":"85","author":"Webley","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0085","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1016\/S0021-9258(19)68695-3","article-title":"5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity","volume":"256","author":"Kufe","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0026-895X(25)14632-4","article-title":"Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture","volume":"21","author":"Glazer","year":"1982","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0095","first-page":"1855","article-title":"Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules","volume":"52","author":"Aschele","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","author":"Piedbois","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0105","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0110","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0115","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0120","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from human liver","volume":"267","author":"Lu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0125","first-page":"832","article-title":"Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years","volume":"23","author":"Saif","year":"2007","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.ctrv.2015.06.001_b0130","first-page":"2085","article-title":"Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2\u2032-tetrahydrofuryl)-5-fluorouracil","volume":"4","author":"Ho","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0135","first-page":"2602","article-title":"Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats","volume":"56","author":"Shirasaka","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"Chuah","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.06.001_b0145","first-page":"134","article-title":"Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28days in patients with solid tumors","volume":"9","author":"Hoff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2015.06.001_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm00331a001","article-title":"Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2\u2032-deoxyuridine","volume":"7","author":"Heidelberger","year":"1964","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0160","first-page":"449","article-title":"Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo","volume":"27","author":"Emura","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0170","first-page":"247","article-title":"The clinical pharmacology of 5-trifluoromethyl-2\u2032-deoxyuridine","volume":"32","author":"Dexter","year":"1972","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0175","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2032-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0180","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0185","first-page":"205","article-title":"Phase I and II studies of 2\u2032-deoxy-5-(trifluoromethyl)-uridine (NSC-75520)","volume":"55","author":"Ansfield","year":"1971","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.ctrv.2015.06.001_b0190","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2015.06.001_b0195","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1081\/NCN-200027707","article-title":"Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells","volume":"23","author":"Temmink","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ctrv.2015.06.001_b0200","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1021\/bi00795a018","article-title":"Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2\u2032-deoxyuridylic acid","volume":"10","author":"Santi","year":"1971","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2015.06.001_b0205","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1021\/bi00254a018","article-title":"Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2\u2032-deoxyuridine 5\u2032-monophosphate","volume":"33","author":"Eckstein","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2015.06.001_b0210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0026-895X(25)14702-0","article-title":"Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides","volume":"1","author":"Reyes","year":"1965","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0215","first-page":"377","article-title":"Fluorinated pyrimidines. XXIV. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2\u2032-deoxyuridine-2-C-14","volume":"25","author":"Heidelberger","year":"1965","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0026-895X(25)15230-9","article-title":"Fluorinated pyrimidines. XXXVII. Effects of 5-trifluoromethyl-2\u2032-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture","volume":"6","author":"Fujiwara","year":"1970","journal-title":"Mol Pharmacol"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2015.06.001_b0225","article-title":"TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer","volume":"50","author":"Oguchi","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0230","first-page":"263","article-title":"Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes","volume":"39","author":"Suzuki","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0235","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-14-0236","article-title":"Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks","volume":"14","author":"Matsuoka","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2015.06.001_b0240","first-page":"249","article-title":"An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA","volume":"13","author":"Emura","year":"2004","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ctrv.2015.06.001_b0245","doi-asserted-by":"crossref","first-page":"39926","DOI":"10.1074\/jbc.M207107200","article-title":"HUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup","volume":"277","author":"Kavli","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0250","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/bi102046h","article-title":"Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA","volume":"50","author":"Grogan","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2015.06.001_b0255","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1093\/nar\/gkr563","article-title":"UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation","volume":"39","author":"Pettersen","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0260","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-06-2960","article-title":"5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity","volume":"67","author":"An","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0265","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1371\/journal.pbio.1000091","article-title":"Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil","volume":"7","author":"Kunz","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0270","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1158\/0008-5472.CAN-05-4488","article-title":"The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine","volume":"66","author":"Turner","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0275","doi-asserted-by":"crossref","first-page":"32422","DOI":"10.1074\/jbc.M004535200","article-title":"Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase","volume":"275","author":"Petronzelli","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0280","doi-asserted-by":"crossref","first-page":"15071","DOI":"10.1073\/pnas.2334585100","article-title":"The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity","volume":"100","author":"Cortellino","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2015.06.001_b0285","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1073\/pnas.92.4.998","article-title":"Thymidine phosphorylase is angiogenic and promotes tumor growth","volume":"92","author":"Moghaddam","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2015.06.001_b0290","doi-asserted-by":"crossref","first-page":"19272","DOI":"10.1074\/jbc.M212670200","article-title":"Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3","volume":"278","author":"Hotchkiss","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.06.001_b0295","first-page":"1911","article-title":"The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors","volume":"59","author":"Matsushita","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0300","first-page":"5345","article-title":"Suppression of metastasis by thymidine phosphorylase inhibitor","volume":"60","author":"Takao","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0305","first-page":"277","article-title":"Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells","volume":"17","author":"Murakami","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1349-7006.1996.tb03161.x","article-title":"Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells","volume":"87","author":"Inaba","year":"1996","journal-title":"Jpn J Cancer Res"},{"issue":"Suppl. 19","key":"10.1016\/j.ctrv.2015.06.001_b0315","article-title":"Efficacy of trifluridine for 5-fluorouracil-resistant human gastric cancer cell lines and their mechanisms","volume":"74","author":"Matsuoka","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0320","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10120-013-0249-7","article-title":"Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase","volume":"17","author":"Nakamura","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0325","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2407-10-370","article-title":"Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells","volume":"10","author":"Sasaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0330","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1038\/cddis.2013.350","article-title":"Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment","volume":"4","author":"Sui","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2015.06.001_b0335","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/ijc.24943","article-title":"Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells","volume":"126","author":"Bijnsdorp","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2006.08.022","article-title":"Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine","volume":"43","author":"Temmink","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0345","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjc.6603549","article-title":"Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells","volume":"96","author":"Temmink","year":"2007","journal-title":"Br J Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2015.06.001_b0350","article-title":"Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenografts","volume":"50","author":"Ishida","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0355","first-page":"2135","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts","volume":"33","author":"Tsukihara","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2015.06.001_b0360","unstructured":"Nukatsuka M, Nakagawa F, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res (in press)."},{"key":"10.1016\/j.ctrv.2015.06.001_b0365","first-page":"1437","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts","volume":"35","author":"Nukatsuka","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2015.06.001_b0370","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/cncr.22125","article-title":"Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors","volume":"107","author":"Hong","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.06.001_b0375","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/07357900802087242","article-title":"Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2015.06.001_b0380","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-008-9142-3","article-title":"Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2015.06.001_b0385","article-title":"Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)","volume":"24","author":"Green","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.06.001_b0390","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/bjc.2012.274","article-title":"Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours","volume":"107","author":"Doi","year":"2012","journal-title":"Br J Cancer"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2015.06.001_b0395","article-title":"A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC)","volume":"30","author":"Patel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2015.06.001_b0400","article-title":"Multicenter phase 2 study of TAS-102 monotherapy in patients with pretreated advanced gastric cancer","volume":"49","author":"Muro","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:56:19Z","timestamp":1748433379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0305737215001231"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.06.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAS-102, a novel antitumor agent: A review of the mechanism of action","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}